EPM Therapeutics
epm Therapeutics is a biotechnology company focused on discovery and preclinical development of synthetic cannabinoid acid derivatives. The company was founded in 2017 in collaboration with the Hebrew University of Jerusalem and restructured in 2023. Its development efforts center on synthetic cannabidiol acid methyl ester candidates for the treatment of hyperphagia associated with Prader-Willi Syndrome; one such candidate has been granted Orphan Drug Designation by the U.S. FDA. The company is preparing for IND submission and is seeking investment to support clinical development.
Industries
N/A
Nr. of Employees
small (1-50)
EPM Therapeutics
7310 Turfway Road, Suite 550, Florence, KY 41042
Products
Preclinical-stage therapeutic candidate (synthetic cannabidiol acid methyl ester)
A preclinical-stage synthetic cannabidiol acid methyl ester development candidate intended for treatment of hyperphagia associated with Prader-Willi Syndrome.
Preclinical-stage therapeutic candidate (synthetic cannabidiol acid methyl ester)
A preclinical-stage synthetic cannabidiol acid methyl ester development candidate intended for treatment of hyperphagia associated with Prader-Willi Syndrome.
Services
Preparation and sharing of investor pitch decks and one-page summaries to support fundraising and investor discussions.
Preparation and sharing of investor pitch decks and one-page summaries to support fundraising and investor discussions.
Expertise Areas
- Cannabinoid-based therapeutics
- Medicinal chemistry and small-molecule discovery
- Preclinical pharmacology and safety evaluation
- Regulatory strategy for orphan drugs
Key Technologies
- Synthetic small-molecule medicinal chemistry
- Cannabinoid derivative chemistry
- Preclinical pharmacology and in vivo evaluation
- Regulatory submission documentation (IND, Orphan Drug interactions)
News & Updates
An FDA Orphan Drug Designation was granted for the company's synthetic cannabidiol acid methyl ester candidate for treatment of hyperphagia in Prader-Willi Syndrome.
Company founded in 2017 in collaboration with the Hebrew University of Jerusalem.
Company restructuring and doing business as epm Therapeutics in 2023.
An FDA Orphan Drug Designation was granted for the company's synthetic cannabidiol acid methyl ester candidate for treatment of hyperphagia in Prader-Willi Syndrome.
Company founded in 2017 in collaboration with the Hebrew University of Jerusalem.
Company restructuring and doing business as epm Therapeutics in 2023.